Back to Search
FRANK HODI, MD
MD
Medical Oncology Physician
NPI: 1730156324IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
80787(MA)
Education
JS WEILL MEDICAL COLLEGE, CORNELL UNIVERSITY
Class of 1992
Research & Publications (20)
Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma.
PMID 18852719·Nat Clin Pract Oncol·2008
8-other
CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.
PMID 18665147·Nat Clin Pract Oncol·2008
5-case
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
PMID 18287062·Proc Natl Acad Sci U S A·2008
3-trial
Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stage.
PMID 16467076·Clin Cancer Res·2006
6-review
Withdrawal of immunosuppression contributing to the remission of malignant melanoma: a case report.
PMID 15901138·Cancer Immun·2005
5-case
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
PMID 12682289·Proc Natl Acad Sci U S A·2003
3-trial
Phase II study of paclitaxel and carboplatin for malignant melanoma.
PMID 12040289·Am J Clin Oncol·2002
3-trial
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.
PMID 11983866·Proc Natl Acad Sci U S A·2002
7-preclinical
Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity.
PMID 18559611·Clin Cancer Res·2008
8-other
Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis.
PMID 18545145·Am J Surg Pathol·2008
3-trial
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
PMID 18445842·J Clin Oncol·2008
3-trial
Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.
PMID 18364009·Immunol Rev·2008
6-review
Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer.
PMID 18311903·J Proteome Res·2008
8-other
Modeling genomic diversity and tumor dependency in malignant melanoma.
PMID 18245465·Cancer Res·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 44 BINNEY ST, DANA FARBER CANCER INSTITUTE
BOSTON, MA 02115 - Phone
- (617) 632-5053
Quick Facts
- NPI
- 1730156324
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile